Logo image of BBNX

BETA BIONICS INC (BBNX) Stock Fundamental Analysis

NASDAQ:BBNX - Nasdaq - US08659B1026 - Common Stock - Currency: USD

19.09  -0.4 (-2.05%)

After market: 19.09 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to BBNX. BBNX was compared to 188 industry peers in the Health Care Equipment & Supplies industry. BBNX has a great financial health rating, but its profitability evaluates not so good. BBNX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year BBNX has reported negative net income.
BBNX had a negative operating cash flow in the past year.
BBNX Yearly Net Income VS EBIT VS OCF VS FCFBBNX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -20M -40M -60M

1.2 Ratios

BBNX has a Return On Assets of -36.59%. This is in the lower half of the industry: BBNX underperforms 60.64% of its industry peers.
Looking at the Return On Equity, with a value of -72.04%, BBNX is in line with its industry, outperforming 42.02% of the companies in the same industry.
Industry RankSector Rank
ROA -36.59%
ROE -72.04%
ROIC N/A
ROA(3y)-86.31%
ROA(5y)N/A
ROE(3y)-215.12%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BBNX Yearly ROA, ROE, ROICBBNX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

BBNX has a Gross Margin of 55.11%. This is comparable to the rest of the industry: BBNX outperforms 51.06% of its industry peers.
BBNX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 55.11%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BBNX Yearly Profit, Operating, Gross MarginsBBNX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 0 -10K -20K -30K

More info and screens

8

2. Health

2.1 Basic Checks

BBNX does not have a ROIC to compare to the WACC, probably because it is not profitable.
BBNX has about the same amout of shares outstanding than it did 1 year ago.
There is no outstanding debt for BBNX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BBNX Yearly Shares OutstandingBBNX Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 10M 20M 30M 40M
BBNX Yearly Total Debt VS Total AssetsBBNX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 50M 100M

2.2 Solvency

An Altman-Z score of 4.30 indicates that BBNX is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 4.30, BBNX is in the better half of the industry, outperforming 74.47% of the companies in the same industry.
There is no outstanding debt for BBNX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4.3
ROIC/WACCN/A
WACC9.05%
BBNX Yearly LT Debt VS Equity VS FCFBBNX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 20M -20M 40M -40M 60M -60M

2.3 Liquidity

BBNX has a Current Ratio of 6.29. This indicates that BBNX is financially healthy and has no problem in meeting its short term obligations.
BBNX has a Current ratio of 6.29. This is amongst the best in the industry. BBNX outperforms 82.98% of its industry peers.
BBNX has a Quick Ratio of 5.66. This indicates that BBNX is financially healthy and has no problem in meeting its short term obligations.
BBNX has a Quick ratio of 5.66. This is amongst the best in the industry. BBNX outperforms 84.57% of its industry peers.
Industry RankSector Rank
Current Ratio 6.29
Quick Ratio 5.66
BBNX Yearly Current Assets VS Current LiabilitesBBNX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

3

3. Growth

3.1 Past

BBNX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -24.17%.
Looking at the last year, BBNX shows a very strong growth in Revenue. The Revenue has grown by 442.93%.
EPS 1Y (TTM)-24.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3.93%
Revenue 1Y (TTM)442.93%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%144.79%

3.2 Future

BBNX is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -4.08% yearly.
Based on estimates for the next years, BBNX will show a very strong growth in Revenue. The Revenue will grow by 33.97% on average per year.
EPS Next Y-12.64%
EPS Next 2Y-6.02%
EPS Next 3Y-4.08%
EPS Next 5YN/A
Revenue Next Year30.63%
Revenue Next 2Y33.26%
Revenue Next 3Y33.97%
Revenue Next 5YN/A

3.3 Evolution

BBNX Yearly Revenue VS EstimatesBBNX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 50M 100M 150M
BBNX Yearly EPS VS EstimatesBBNX Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

BBNX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BBNX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BBNX Price Earnings VS Forward Price EarningsBBNX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BBNX Per share dataBBNX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

BBNX's earnings are expected to decrease with -4.08% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-6.02%
EPS Next 3Y-4.08%

More info and screens

0

5. Dividend

5.1 Amount

BBNX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BETA BIONICS INC

NASDAQ:BBNX (6/13/2025, 8:00:01 PM)

After market: 19.09 0 (0%)

19.09

-0.4 (-2.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-07 2025-05-07/bmo
Earnings (Next)N/A N/A
Inst Owners93.3%
Inst Owner ChangeN/A
Ins Owners6.51%
Ins Owner Change98.94%
Market Cap827.74M
Analysts83.08
Price Target24.19 (26.72%)
Short Float %9.28%
Short Ratio6.24
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-7.78%
PT rev (3m)-10.27%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-14.7%
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)-1.42%
Revenue NQ rev (3m)-1.91%
Revenue NY rev (1m)0.14%
Revenue NY rev (3m)-0.41%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 12.71
P/FCF N/A
P/OCF N/A
P/B 10.89
P/tB 10.89
EV/EBITDA N/A
EPS(TTM)-1.28
EYN/A
EPS(NY)-2.4
Fwd EYN/A
FCF(TTM)-1.19
FCFYN/A
OCF(TTM)-1.11
OCFYN/A
SpS1.5
BVpS1.75
TBVpS1.75
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -36.59%
ROE -72.04%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 55.11%
FCFM N/A
ROA(3y)-86.31%
ROA(5y)N/A
ROE(3y)-215.12%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.44
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 148.71%
Cap/Sales 5.21%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.29
Quick Ratio 5.66
Altman-Z 4.3
F-Score5
WACC9.05%
ROIC/WACCN/A
Cap/Depr(3y)68.31%
Cap/Depr(5y)N/A
Cap/Sales(3y)146.62%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-24.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3.93%
EPS Next Y-12.64%
EPS Next 2Y-6.02%
EPS Next 3Y-4.08%
EPS Next 5YN/A
Revenue 1Y (TTM)442.93%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%144.79%
Revenue Next Year30.63%
Revenue Next 2Y33.26%
Revenue Next 3Y33.97%
Revenue Next 5YN/A
EBIT growth 1Y-26.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-42.99%
EBIT Next 3Y-18.61%
EBIT Next 5YN/A
FCF growth 1Y-57.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-48.78%
OCF growth 3YN/A
OCF growth 5YN/A